(S (NP (DT The) (JJ current) (NN pandemic)) (VP (VBZ has) (VP (VBN highlighted) (NP (NP (DT the) (NN need)) (PP (IN for) (NP (NP (NNS methodologies)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (ADVP (RB quickly) (CC and) (RB reliably)) (VB prioritize) (NP (ADJP (RB clinically) (VBN approved)) (NNS compounds)) (PP (IN for) (NP (NP (PRP$ their) (JJ potential) (NN effectiveness)) (PP (IN for) (NP (NNP SARS-CoV-2) (NNS infections)))))))))))))) (. .))
(S (PP (IN In) (NP (DT the) (JJ past) (NN decade))) (, ,) (NP (NN network) (NN medicine)) (VP (VBZ has) (VP (VBN developed) (CC and) (VBN validated) (NP (NP (JJ multiple) (JJ predictive) (NN algorithms)) (PP (IN for) (NP (NN drug) (NN repurposing)))) (, ,) (S (VP (VBG exploiting) (NP (NP (DT the) (ADJP (JJ sub-cellular) (JJ network-based)) (NN relationship)) (PP (IN between) (NP (NP (NP (DT a) (NN drug) (POS 's)) (NX (NNS targets))) (CC and) (NX (NN disease) (NNS genes))))))))) (. .))
(S (ADVP (RB Here)) (, ,) (NP (PRP we)) (VP (VBD deployed) (NP (NP (RP algorithms)) (VP (VBG relying) (PP (IN on) (NP (NP (JJ artificial) (NN intelligence)) (, ,) (NP (NN network) (NN diffusion)) (, ,) (CC and) (NP (NN network) (NN proximity)))))) (, ,) (S (VP (VBG tasking) (NP (NP (DT each)) (PP (IN of) (NP (PRP them)))) (S (VP (TO to) (VP (VB rank) (NP (CD 6,340) (NNS drugs)) (PP (IN for) (NP (NP (PRP$ their) (VBN expected) (NN efficacy)) (PP (IN against) (NP (NNP SARS-CoV-2))))))))))) (. .))
(S (S (VP (TO To) (VP (VB test) (NP (DT the) (NNS predictions))))) (, ,) (NP (PRP we)) (VP (VBD used) (PP (IN as) (NP (NN ground) (NN truth))) (NP (NP (NP (CD 918) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBD had) (VP (VBN been) (VP (ADVP (RB experimentally)) (VBN screened) (PP (IN in) (NP (NNP VeroE6) (NNS cells))))))))) (, ,) (CC and) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (NP (NNS drugs)) (PP (IN under) (NP (JJ clinical) (NN trial)))))) (, ,) (SBAR (WHNP (WDT that)) (S (VP (VBP capture) (NP (NP (NP (DT the) (JJ medical) (NN community) (POS 's)) (NN assessment)) (PP (IN of) (NP (NP (NNS drugs)) (PP (IN with) (NP (JJ potential) (NNP COVID-19) (NN efficacy))))))))))) (. .))
(S (NP (PRP We)) (VP (VBP find) (SBAR (DT that) (S (SBAR (IN while) (S (NP (JJS most) (NNS algorithms)) (VP (VBP offer) (NP (JJ predictive) (NN power)) (PP (IN for) (NP (DT these) (NN ground) (NN truth) (NNS data)))))) (, ,) (NP (DT no) (JJ single) (NN method)) (VP (NNS offers) (NP (ADJP (RB consistently) (JJ reliable)) (NNS outcomes)) (PP (IN across) (NP (DT all) (NNS datasets) (CC and) (NNS metrics))))))) (. .))
(S (NP (DT This)) (VP (VBD prompted) (S (NP (PRP us)) (VP (TO to) (VP (VB develop) (NP (NP (DT a) (JJ multimodal) (NN approach)) (SBAR (WHNP (WDT that)) (S (VP (VBZ fuses) (NP (NP (DT the) (NNS predictions)) (PP (IN of) (NP (DT all) (NNS algorithms)))))))) (, ,) (S (VP (VBG showing) (SBAR (IN that) (S (NP (NP (DT a) (NN consensus)) (PP (IN among) (NP (DT the) (JJ different) (JJ predictive) (NNS methods)))) (VP (ADVP (RB consistently)) (VBZ exceeds) (NP (NP (DT the) (NN performance)) (PP (IN of) (NP (DT the) (JJS best) (JJ individual) (NNS pipelines))))))))))))) (. .))
(S (NP (PRP We)) (VP (VBP find) (SBAR (IN that) (S (NP (NP (CD 76)) (PP (IN of) (NP (NP (DT the) (CD 77) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (ADVP (RB successfully)) (VBD reduced) (NP (JJ viral) (NN infection)))))))) (VP (VBP do) (RB not) (VP (VB bind) (NP (NP (DT the) (NNS proteins)) (VP (VBN targeted) (PP (IN by) (NP (NNP SARS-CoV-2))))) (, ,) (S (VP (VBG indicating) (SBAR (IN that) (S (NP (DT these) (NNS drugs)) (VP (VBP rely) (PP (IN on) (NP (NP (JJ network-based) (NNS actions)) (SBAR (WHNP (WDT that)) (S (VP (MD can) (RB not) (VP (VB be) (VP (VBN identified) (S (VP (VBG using) (NP (JJ docking-based) (NNS strategies))))))))))))))))))))) (. .))
(S (NP (DT These) (NNS advances)) (VP (VBP offer) (NP (NP (DT a) (JJ methodological) (NN pathway)) (SBAR (S (VP (TO to) (VP (VB identify) (NP (NP (JJ repurposable) (NNS drugs)) (PP (IN for) (NP (NP (NP (JJ future) (NNS pathogens)) (CC and) (NP (JJ neglected) (NNS diseases))) (VP (VBN underserved) (PP (IN by) (NP (NP (DT the) (NX (NX (NNS costs)) (CC and) (NX (JJ extended) (NN timeline)))) (PP (IN of) (NP (FW de) (FW novo) (NN drug) (NN development))))))))))))))) (. .))
